Human services: medical services; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109t.
Impact
The passage of SB 717 would bring substantial changes to the way prescription drugs for menopause and perimenopause are managed under the state medical assistance program. By eliminating prior authorization requirements for specific medications, the bill is expected to improve access to treatments, reducing delays which can adversely affect patient health outcomes. This change would directly influence how healthcare providers prescribe medications and how patients access necessary care. Furthermore, the bill underscores a commitment to ensure that women’s health issues receive appropriate attention and support within the healthcare system.
Summary
Senate Bill 717 aims to amend the Social Welfare Act by specifically addressing the prescription drug coverage for menopause and perimenopause symptoms. The bill proposes that the department responsible for medical assistance programs will not require prior authorization for certain prescription drugs, including those related to the treatment of menopause and perimenopause symptoms. This amendment reflects an effort to simplify access to necessary medications for women experiencing these natural life stages by reducing bureaucratic hurdles. Notably, the bill emphasizes the importance of providing medically necessary care and treatments which are recognized by health authorities, thereby aligning prescription practices with accepted medical standards.
Contention
While the bill aims to streamline access to treatment for menopause and perimenopause symptoms, it may face scrutiny from various stakeholders regarding the implications of removing prior authorization. Critics may express concerns about the potential for increased insurance costs or misuse of medications without the oversight typically provided by prior authorization protocols. Supporters of the bill argue that the benefits of ensuring timely access to care outweigh these concerns, especially considering the prevalence of menopause-related conditions among women. Thus, illuminating a discussion about balancing regulatory oversight with patient care needs remains a central point of contention surrounding SB 717.
Human services: medical services; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109t.
Insurance: health insurers; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406zz.
Insurance: health insurers; coverage for treatment of menopause and perimenopause symptoms and waiver of prior authorization for prescription drugs or treatments for menopause and perimenopause symptoms; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406zz.
Human services: medical services; exemption of certain prescription drugs for the treatment or management of pain from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109v.
Human services: medical services; exemption of certain prescription drugs from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h).
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.